title: Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.
abstract: OBJECTIVE
  This study was designed to retrospectively evaluate the diagnostic yield of FDG PET for the diagnosis of recurrent ovarian cancer.
  
  
  METHODS
  Eighty FDG PET scans were performed on 55 patients owing to suspicion of relapse, and 45 FDG PET scans were performed on 31 patients who were clinically disease free. PET results were compared with the results of conventional radiological imaging (CIM) and serum CA 125 levels, and related to pathological findings in 54 cases or clinical follow-up in 71 cases.
  
  
  RESULTS
  CIM correctly identified 49 cases with recurrence [sensitivity (SE) 53.3%] ,and there were 27 true negatives [specificity (SP) 81.8%] However, 43 cases were false negative and six were false positive. The positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACC) of CIM were 89%, 38.6% and 60.8%, respectively. FDG PET correctly detected recurrent disease in 80/92 cases (SE 86.9%, p<0.05) and ruled out relapse in 26/33 cases (SP=78.8%). The PPV, NPV and ACC of PET were 91.9%, 68.4% and 84.8%, respectively. Standardised uptake values did not provide additional diagnostic accuracy compared with visual analysis. The CA 125 results showed an SE of 57.6%, an SP of 93.9% and an ACC of 67.2%. In 23 patients with positive serum CA 125 levels, but negative CIM, FDG PET was positive and relapse was confirmed. Furthermore, FDG PET was positive and relapse was confirmed in 11 patients with negative serum CA 125 levels and CIM.
  
  
  CONCLUSIONS
  FDG PET may detect recurrent ovarian cancer earlier than CIM, with higher sensitivity and even higher diagnostic accuracy.
authors.affiliation: Department of Nuclear Medicine, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Avda. Pío XII, 36, 31008, Pamplona, Spain. mjgarciave@unav.es
authors.forename: María José
authors.initials: MJ
authors.lastname: García-Velloso
authors.forename: Matías
authors.initials: M
authors.lastname: Jurado
authors.forename: Carolina
authors.initials: C
authors.lastname: Ceamanos
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Aramendía
authors.forename: María Puy
authors.initials: MP
authors.lastname: Garrastachu
authors.forename: Guillermo
authors.initials: G
authors.lastname: López-García
authors.forename: José Angel
authors.initials: JA
authors.lastname: Richter
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000494:pharmacology*; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D012008:Recurrence; D015203:Reproducibility of Results; D051598:Whole Body Imaging
chemical_list: D000970:Antineoplastic Agents; D018394:CA-125 Antigen; D019788:Fluorodeoxyglucose F18; D002945:Cisplatin